Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Sanofi
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
NRG Oncology
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
ModernaTX, Inc.
Atara Biotherapeutics
Pierre Fabre Medicament
Pierre Fabre Medicament
National Institutes of Health Clinical Center (CC)
SymBio Pharmaceuticals
Chinese PLA General Hospital
University Hospital, Basel, Switzerland
Institut Pasteur du Cambodge
National Taiwan University Hospital
Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
Baylor College of Medicine
Institute of Hematology & Blood Diseases Hospital, China
Centre Hospitalier Universitaire de Nīmes
University of Aarhus
Stanford University
Thomas Jefferson University
Emory University
ModernaTX, Inc.
Sun Yat-sen University
The Affiliated Hospital of Xuzhou Medical University
National Health Research Institutes, Taiwan
Stanford University
New York Medical College
Baylor College of Medicine
Baylor College of Medicine
Columbia University
Viracta Therapeutics, Inc.
University Hospital Freiburg
National Institutes of Health Clinical Center (CC)
Baylor College of Medicine
Marengo Therapeutics, Inc.
University of Pittsburgh
National Institutes of Health Clinical Center (CC)
ModernaTX, Inc.
Maisonneuve-Rosemont Hospital
Pediatric Transplantation & Cellular Therapy Consortium
Centre Hospitalier Universitaire de Nice
Atara Biotherapeutics
University of California, San Francisco
Sun Yat-sen University
University Hospital, Basel, Switzerland